Journal of NeuroVirology

, Volume 12, Issue 1, pp 39–46 | Cite as

JC virus in the Irish population: Significant increase of genotype 2 in immunocompromised individuals

  • Kirsten Schaffer
  • Noreen Sheehy
  • Suzie Coughlan
  • Colm Bergin
  • William W. Hall
Article

Abstract

The human polyomavirus JC virus (JCV) is ubiquitous and can be shed in the urine of more than 40% of the healthy population. Amplification and sequencing of JCV from urine has allowed a distinctive map of the distribution of JCV genotypes worldwide. To define the frequency of JCV urinary excretion and genotype distribution in Ireland, urines from 121 healthy individuals and from 94 immunocompromised individuals (human immunodeficiency virus [HIV]-positive patients and rheumatoid arthritis patients) were collected. JCV DNA was detected by polymerase-chain reaction (PCR) with subsequent nucleotide sequencing of a fragment of the major capsid protein (VP1). JCV was detected in 20.7% of healthy individuals and was found significantly more often in the urine of HIV-positive patients (54.2%; P < .001) and rheumatoid arthritis patients (54.4%; P < .001). In healthy Irish individuals genotype 1 was the predominant genotype in 62.5%, followed by genotype 4 in 16.7% and genotype 2 in 12.5%. In contrast, genotype 2 was significantly more often isolated from the urine of both HIV-positive patients (60%) and rheumatoid arthritis patients (54.4%; P < .01). The pattern of genotype distribution among healthy Irish individuals is in agreement with data reported from other European countries, whereas the overall level of JCV urinary excretion is lower. Previous studies have found genotype 2 significantly more often in cerebrospinal (CSF) samples of patients with progressive multifocal leukoencephalopathy (PML). Here the authors report an increased frequency of genotype 2 in urine samples of immunocompromised non-PML patients. This finding further underlines the hypothesis that there could be biologic differences between JCV genotypes.

Keywords

genotypes immunodeficiency JC virus VP1 gene 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, Frias C, Perez-Trallero E, Ryschkewitsch CF, Stoner GL (2001). Genotypes of JC virus in East, Central and Southwest Europe. J Gen Virol 82: 1221–1331.PubMedGoogle Scholar
  2. Agostini HT, Ryschkewitsch CF, Mory R, Singer EJ, Stoner GL (1997). JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: increased frequency of JCV type 2 in PML. J Infect Dis 176: 1–8PubMedCrossRefGoogle Scholar
  3. Agostini HT, Ryschkewitsch CF, Singer EJ, Baumhefner RW, Stoner GL (1998a). JC virus type 2B is found more frequently in brain tissue of progressive multifocal leukoencephalopathy patients than in urine from controls. J Hum Virol 3: 200–206.Google Scholar
  4. Agostini HT, Ryschkewitsch CF, Stoner GJ (1998b). JC virus type 1 has multiple subtypes: three new complete genomes. J Gen Virol 79: 801–805.PubMedGoogle Scholar
  5. Agostini HT, Shishido-Hara Y, Baumhefner RW, Singer EJ, Ryschkewitsch CF, Stoner GL (1998c). JC virus type 2: definition of subtypes based on DNA sequence analysis of ten complete genomes. J Gen Virol 79: 1143–1151.PubMedGoogle Scholar
  6. Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Khoo SH (2004). Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. J Clin Virol 29: 224–229.PubMedCrossRefGoogle Scholar
  7. Berger JR (2003). Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J NeuroVirol 9(Suppl l): 38–41.PubMedGoogle Scholar
  8. Centers for Disease Control and Prevention (CDC) (2004). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002–2003. MMWR Morb Mortal Wkly Rep 53: 683–686.Google Scholar
  9. Daniel DC, Wortman MJ, Schiller RJ, Liu H, Gan L, Mellen JS, Chang C-F, Gallia GL, Rappaport J, Khalili K, Johnson EM (2001). Coordinate effects of human immunodeficiency virus type 1 protein Tat and cellular protein Purα on DNA replication initiated at the JC virus origin. J Gen Virol 82: 1543–1553.PubMedGoogle Scholar
  10. Dubois V, Moret H, Lafon M-E, Brodard V, Icart J, Ruffault A, Guist’hau O, Buffet-Janvresse C, Abbed K, Dussaix E, Ingrand D (2001). JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 183: 213–217.PubMedCrossRefGoogle Scholar
  11. Ferrante P, Mediati M, Caldarelli-Stefano R, Losciale L, Manusco R, Cagni AE, Maserati R (2001). Increased frequency of JC virus type 2 and of dual infection with JC virus type 1 and 2 in Italian progressive multifocal leukoencephalopathy patients. J NeuroVirol 7: 35–42.PubMedCrossRefGoogle Scholar
  12. Frisque RJ, Bream GL, Cannella MT (1984). Human polyomavirus JC virus genome. J Virol 51: 458–469.PubMedGoogle Scholar
  13. Hatwell JN, Sharp PM (2000). Evolution of human polyomavirus JC. J Gen Virol 81: 1191–1200.PubMedGoogle Scholar
  14. Kitamura T, Kunitake T, Quo J, Tominaga T, Kawabe K, Yogo Y (1994). Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J Clin Microbiol 32: 2359–2363.PubMedGoogle Scholar
  15. Kleinschmidt-DeMasters BK, Tyler KL (2005). Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369–374.PubMedCrossRefGoogle Scholar
  16. Krachmarov CP, Chepenik LG, Barr-Vagell S, Khalili K, Johnson EM (1996). Activation of the JC virus Tatresponsive transcriptional control element by association of the Tat protein of human immunodeficiency virus 1 with cellular protein Purα. Proc Natl Acad Sci U S A 93: 14112–14117.PubMedCrossRefGoogle Scholar
  17. Lednicky JA, Vilchez RA, Keitel WA, Visnegarwala F, White ZS, Kozinetz CA, Lewis DE, Butel JS (2003). Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17: 801–807.PubMedCrossRefGoogle Scholar
  18. Major EO (2001). Human polyomavirus. In: Virology. Fields BN, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE, Knipe DM (eds). Philadelphia: Lippincott Williams, pp 2175–2196.Google Scholar
  19. Pagani E, Delbue S, Manusco R, Borghi E, Tarantini L, Ferrante P (2003). Molecular analysis of JC virus genotypes circulating among the Italian healthy population. J NeuroVirol 9: 559–566.PubMedGoogle Scholar
  20. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J (2003). Seroepidemiology of the human polyomaviruses. J Gen Virol 84: 1499–1504.PubMedCrossRefGoogle Scholar
  21. Sundsfjord A, Flaegstad T, Flo R, Spein AR, Pedersen M, Permin H, Julsrud J, Traavik T (1994). BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions. J Infect Dis 169: 485–490.PubMedCrossRefGoogle Scholar
  22. Tsai R-T, Wang M, Ou W-C, Lee Y-L, Li S-Y, Fung C-Y, Huang Y-L, Tzeng T-Y, Chen Y, Chang D (1997). Incidence of JC viruria is higher than that of BK viruria in Taiwan. J Med Virol 52: 253–257.PubMedCrossRefGoogle Scholar
  23. Van Assche G, Van Raust M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005). Progressive multifocal leukoencephalopathy after natalizumab therapy for Chron’s disease. N Engl J Med 353(4): 362–368.PubMedCrossRefGoogle Scholar
  24. Venter M, Smit SB, Leman P, Swanepoel R (2004). Phylogenetic evidence of widespread distribution of genotype 3 JC virus in Africa and identification of a type 7 isolate in an African AIDS patient. J Gen Virol 85: 2215–2219.PubMedCrossRefGoogle Scholar
  25. Wang M, Tsai R-T, Ou W-C, Lin C-K, Tsay GJ, Chang H, Chang D (2000). Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease. J Med Virol 62: 505–510.PubMedCrossRefGoogle Scholar
  26. Yanagihara R, Nerurkar VR, Scheirich I, Agostini HT, Mgone CS, Cui X, Jobes DV, Cubitt CL, Ryschkewitsch CF, Hroly DB, Friedlaender JS, Stoner GL (2002). JC virus genotypes in the western Pacific suggest Asian mainland relationships and virus association with early population movements. Hum Biol 74: 473–488.PubMedCrossRefGoogle Scholar
  27. Zheng H-Y, Takasaka T, Noda K, Kanazawa A, Mori H, Kabuki T, Joh K, Oh-ishi T, Ikegaya H, Nagashima K, Hall WW, Kitamura T, Yogo Y (2005). New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J Gen Virol 86: 2035–2045.PubMedCrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2006

Authors and Affiliations

  • Kirsten Schaffer
    • 1
    • 2
  • Noreen Sheehy
    • 1
  • Suzie Coughlan
    • 2
  • Colm Bergin
    • 3
  • William W. Hall
    • 1
    • 2
  1. 1.Department of Medical Microbiology, Centre for Research in Infectious DiseasesUniversity College DublinDublinIreland
  2. 2.National Virus Reference LaboratoryUniversity College DublinDublinIreland
  3. 3.Department of Infectious DiseasesSt James’s HospitalDublinIreland

Personalised recommendations